New Pharmaceuticals market report from Espicom Business Intelligence: "Generic Drugs: Global collaboration opportunities"
Boston, MA -- (SBWIRE) -- 04/07/2014 -- Key facts, statistics and insights on 160 medium-sized generic manufacturers based in 42 countries!
Collaboration is the key to growth
With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems.
At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of branded medicines have made moves to increase generic prescribing.
But pressure on health spending is seeing downward pressure on generic prices. With lower margins this is creating pain for generics companies.
SME Generic companies offer focused opportunities
With established markets compromised, where can the industry go? Expansion in the sector has been seen through more partnering, either through outright acquisition to increase market share or through product and marketing licensing. Being bigger and having improved market access is seen as a way of distributing cost and strengthening revenues. While major players such as Teva and Sandoz play an international role, there are a number of established and progressive generic manufacturers worthy of consideration.
View Full Report Details and Table of Contents
Use this report to...
Identify commercial partners to secure new markets, technologies and revenues
Assess merger and acquisition targets
Understand the developing generic industry in key markets worldwide
Profile the competitive environment in the increasingly important medium-sized company sector
Seek out companies manufacturing/marketing similar product lines
Assess the investment potential of these key companies
Find and assess potential partners and acquisition targets with this report
This new report from Espicom is a key resource for the wide assessment of 160 medium-sized generic companies operating in 42 markets worldwide. The report provides an essential and comprehensive evaluation of each company:
Location, establishment and full contact details
Financial information, where available
Products and/or therapy areas
Recent strategic alliances
Delivering the key content you need...
A summary of the company's foundation and main business interests
- Product range
Details of ANDAs approved or products/therapy areas represented
Financial performance or funding data
- Strategic alliances
Details of significant marketing and supply agreements
- Contact information
Postal, telephone, fax and website details
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Biosimilars Market - Global Forecast to 2018
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US
- The World Generic Market Report 2013 (Volume 1 & 2)
- Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use
- Pfizer Inc. - Product Pipeline Review - 2013
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany
- Healthcare, Regulatory and Reimbursement Landscape - Norway
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China
- AstraZeneca PLC - Product Pipeline Review - 2013
- Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019